LENZ Therapeutics reported a Q result of a $1.16 loss per share versus the Zacks consensus loss of $0.91 (a $0.25 miss) and versus a $0.46 loss a year ago (loss widened by $0.70 YoY). The results indicate a material deterioration in profitability year-over-year and underperformance relative to analyst expectations, likely exerting downward pressure on the stock near term.
LENZ Therapeutics reported a Q result of a $1.16 loss per share versus the Zacks consensus loss of $0.91 (a $0.25 miss) and versus a $0.46 loss a year ago (loss widened by $0.70 YoY). The results indicate a material deterioration in profitability year-over-year and underperformance relative to analyst expectations, likely exerting downward pressure on the stock near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.60
Ticker Sentiment
